Case studies
The Science Behind’s versatile and integrated approach unlocks early objective insights into target engagement and drug effect.
These case studies provide detailed summaries to showcase some of the solutions and services The Science Behind has delivered for both biotech/pharmaceutical and CRO clients.
The Science Behind Supports Synendos Therapeutics' Successful Phase I Clinical Trial at Richmond Pharmacology
The Science Behind (TSB) is proud to have supported Synendos Therapeutics’ first-in-human Phase I clinical trial of SYT-510, a novel Selective Endocannabinoid Reuptake Inhibitor (SERI), conducted at Richmond Pharmacology.
Pharmaco-TMS and qEEG in Rare Myclonic Epilepsy Condition
TMS-EDMs assess target engagement of novel ion
channel positive modulator for rare genetic form of myoclonic epilepsy.
Specialist Neurology Personnel for Parkinson’s trial
Search, selection and recruitment of specialist for medical procedures for a phase Ib clinical trial, in patients with Parkinson’s Disease.